AstraZeneca said combining its Forxiga type-2 diabetes drug with older medicine Bydureon was more effective at controlling blood sugar levels than treatment with either drug on its own. In a late stage trial, Forxiga and Bydureon were tested on patients whose blood sugar levels could no longer be sufficiently kept in check under an initial standard diabetes therapy with metformin.
Original post:
Astrazeneca says Forxiga combination beats use of drug alone